Recombinant Human PD-1 His Tagged Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Programmed Death-1 receptor (PD-1), also known as CD279, is type I transmembrane protein belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA-4, ICOS, and BTLA (2-5). Mature human PD-1 consists of a 148 amino acid (aa) extracellular region (ECD) with one immunoglobulin-like V-type domain, a 24 aa transmembrane domain, and a 95 aa cytoplasmic region. The human PD-1 ECD shares 65% aa sequence identity with the mouse PD-1 ECD. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. PD-1 acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD‑1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligation of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1: PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11). Finally, blockade of the PD-1: PD-L1 interaction by either antibodies or genetic manipulation accelerates tumor eradication and shows potential for improving cancer immunotherapy (12, 13, 14).

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 4 applications: Bioassay, In Vivo, Surface Plasmon Resonance (SPR, Surface Plasmon Resonance (SPR).

Showing Publications 1 - 8 of 8.

Publications using 8986-PD	Applications	Species
Carter, R;Alanazi, F;Sharp, A;Roman, J;Luchini, A;Liotta, L;Paige, M;Brown, AM;Haymond, A; Identification of the Functional PD-L1 Interface Region Responsible for PD-1 Binding and Initiation of PD-1 Signaling The Journal of biological chemistry 2023-10-17 [PMID: 37858677] (Surface Plasmon Resonance (SPR), Human)	Surface Plasmon Resonance (SPR)	Human
CE Kang, S Lee, T Ahn, DH Seo, BJ Ko, M Jung, J Lee, JY Kim, WT Kim Antibody-dependent cellular cytotoxicity-null effector developed using mammalian and plant GlycoDelete platform Scientific Reports, 2022-11-08;12(1):19030. 2022-11-08 [PMID: 36347901] (Bioassay, Human)	Bioassay	Human
T Phakham, C Boonkrai, T Wongtangpr, T Audomsun, C Attakitban, P Saelao, P Muanwien, S Sooksai, N Hirankarn, T Pisitkun Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development Scientific Reports, 2022-10-22;12(1):17792. 2022-10-22 [PMID: 36273231] (In Vivo, Mouse)	In Vivo	Mouse
H Issafras, S Fan, CL Tseng, Y Cheng, P Lin, L Xiao, YJ Huang, CH Tu, YC Hsiao, M Li, YH Chen, CH Ho, O Li, Y Wang, S Chen, Z Ji, E Zhang, YT Mao, E Liu, S Yang, W Jiang Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy PLoS ONE, 2021-12-31;16(12):e0257972. 2021-12-31 [PMID: 34972111] (Bioassay, Human)	Bioassay	Human
CJ Edwards, A Sette, C Cox, B Di Fiore, C Wyre, D Sydoruk, D Yadin, P Hayes, S Stelter, PD Bartlett, M Zuazo, MJ Garcia-Gra, G Benedetti, S Fiaska, NR Birkett, Y Teng, C Enever, H Arasanz, A Bocanegra, L Chocarro, G Fernandez, R Vera, B Archer, I Osuch, M Lewandowsk, YM Surani, G Kochan, D Escors, J Legg, AJ Pierce The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity British Journal of Cancer, 2021-12-30;0(0):. 2021-12-30 [PMID: 34969998] (Bioassay, Human)	Bioassay	Human
M Metz, G Sussman, R Gagnon, P Staubach, T Tanus, WH Yang, JJ Lim, HJ Clarke, J Galanter, LW Chinn, T Chu, A Teterina, T Burgess, DJ Haddon, TT Lu, M Maurer Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial Nature Medicine, 2021-11-08;27(11):1961-1969. 2021-11-08 [PMID: 34750553] (Bioassay, Human)	Bioassay	Human
ME Brown, D Bedinger, A Lilov, P Rathanaswa, M Vásquez, S Durand, I Wallace-Mo, L Zhong, JH Nett, I Burnina, I Caffry, H Lynaugh, M Sinclair, T Sun, J Bukowski, Y Xu, YN Abdiche Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors PLoS ONE, 2020-03-05;15(3):e0229206. 2020-03-05 [PMID: 32134960] (Bioassay, Human)	Bioassay	Human
M Crauwels, N Van Vaeren, B Kulaya Nee, C Vincke, M D'Huyvette, N Devoogdt, S Muylderman, C Xavier Reshaping Nanobodies for affinity purification on protein A N Biotechnol, 2020-01-27;0(0):. 2020-01-27 [PMID: 32001339] (Surface Plasmon Resonance (SPR, Human)	Surface Plasmon Resonance (SPR	Human

Array 8986-PD

• PD-1 Antibodies
• PD-1 Antibody Pair
• PD-1 Lysate
• PD-1 Proteins
• PD-1 Proteins and Enzymes
• PD-1 ELISAs